Epidemiology and aetiology of moderate to severe diarrhoea in hospitalised HIV-infected patients

≥5 years old in South Africa, 2018-2021: a case-control analysis

3 Authors and affiliations

1

2

5

7

8

9

10

13

14

15

17

19

23

24

Siobhan L. Johnstone<sup>1,2</sup>, Linda Erasmus<sup>1</sup>, Juno Thomas<sup>1</sup>, Michelle J. Groome<sup>3,4</sup>, Nicolette M. du 4

Plessis<sup>5</sup>, Theunis Avenant<sup>5</sup>, Maryke de Villiers<sup>6</sup>, Nicola A. Page<sup>1,7</sup>

6 <sup>1</sup>Center for Enteric Diseases, National Institute for Communicable Diseases, a division of the National

Health Laboratory Service (NHLS), Johannesburg, South Africa; <sup>2</sup>School of Public Health, Faculty of

Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; <sup>3</sup>Division of Public

Health Surveillance and Response, National Institute for Communicable Diseases, a division of the

National Health Laboratory Service (NHLS), Johannesburg, South Africa; <sup>4</sup> School of Pathology,

11 Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa;

12 <sup>5</sup>Department of Paediatrics, Kalafong Provincial Tertiary Hospital, Faculty of Health Sciences,

University of Pretoria, Pretoria 0001, South Africa; <sup>6</sup> Department of Internal Medicine, Kalafong

Provincial Tertiary Hospital, Faculty of Health Sciences, University of Pretoria, Pretoria 0001, South

Africa; <sup>7</sup>Department of Medical Virology, Faculty of Health Sciences, University of Pretoria, Private

16 Bag X323, Arcadia, 0007;.

Corresponding author: Siobhan L. Johnstone; <a href="mailto:siobhanj@nicd.ac.za">siobhanja@gmail.com</a>; (+27)

73 332 7905 18

Short title: Aetiology of diarrhoea in hospitalised HIV-infected patients

20 Key words: Diarrhoea, diagnostics, aetiology, HIV, South Africa

21 Authors' contributions

22 S.L.J, N.A.P, M.J.G, L.E and J.T conceptualised and designed the study. S.L.J, N.A.P, N.D., T.A. and

M.dV completed and managed fieldwork and data collection. S.L.J, N.A.P, M.J.G, L.E and J.T acquired,

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. analysed and interpreted the data. S.L.J drafted the work. All authors reviewed the manuscript.

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

**Abstract** Diarrhoea is a recognised complication of HIV-infection, yet there are limited local aetiological data in this high-risk group. These data are important for informing public health interventions and updating diagnostic and treatment guidelines. This study aimed to determine the pathogenic causes for diarrhoeal admissions in HIV-infected patients compared to hospital controls between July 2018 and November 2021. Admitted diarrhoeal cases (n=243) and non-diarrhoeal hospital controls (n=101) ≥5 years of age were enrolled at Kalafong, Mapulaneng and Matikwana hospitals. Stool specimens/rectal swabs were collected and pathogen screening performed on multiple platforms. Differences in pathogen detections between cases and controls, stratified by HIV status, were investigated. The majority (n=164, 67.5%) of diarrhoeal cases with known HIV status were HIV-infected. Pathogens could be detected in 66.3% (n=228) of specimens, with significantly higher detection in cases compared to controls (72.8% versus 50.5%, p<0.001). Amongst HIV-infected participants, prevalence of Cystoisospora spp. was significantly higher in cases than controls (17.7% versus 0.0%, p=0.028), while Schistosoma was detected more often in controls than cases (17.4% versus 2.4%, p=0.009). Amongst the HIV-uninfected participants, prevalence of Shigella spp., Salmonella spp. and Helicobacter pylori was significantly higher in cases compared to controls (36.7% versus 12.0%, p=0.002; 11.4% versus 0.0%, p=0.012; 10.1% versus 0.0%, p=0.023). Diarrhoeal aetiology differed by HIV status, with Shiqella spp. (36.7%) and Salmonella spp. (11.4%) having the highest prevalence amongst HIV-uninfected cases and Shigella spp. (18.3%), Cystoisospora (17.7%), and Cryptosporidium spp. (15.9%) having the highest prevalence amongst HIV-infected cases. These differences should be considered for the development of diagnostic and treatment guidelines.

Introduction

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

Diarrhoeal diseases pose a significant health burden across the globe, causing over 1.6 million deaths annually amongst all ages1. The majority of these deaths occur in low- and middle-income countries (LMICs), specifically in south Asia and Sub-Saharan Africa (SSA)<sup>1</sup>. Despite a decrease in global diarrhoeal mortality rates over the past two decades, decreases have not been uniform across age groups or settings<sup>2</sup>. Unsafe water, poor sanitation and hygiene (WaSH)<sup>1</sup>, as well as malnutrition and compromised immunity<sup>3</sup> are the main risk factors associated with diarrhoeal morbidity and mortality. Other risk factors identified in LMICs include residence in a slum, use of communal toilets and exposure to animals<sup>4</sup>. Children under the age of 5 years are at the highest risk, however there is a significant burden in older age groups, specifically in LMICs<sup>1,5</sup>. Despite global improvements in WaSH<sup>6</sup>, much of the remaining burden of diarrhoeal disease may be attributed to foodborne pathogens<sup>7</sup>. Food safety is of specific concern in LMICs where there is increased consumption of unsafe foods, use of effluent in agriculture and changes in food distribution networks with bulk production and increased distance between production and consumption as well as large, often poorly regulated, informal sectors<sup>7</sup>. Studies from high-income countries (HICs) have shown the majority of diarrhoeal diseases in adults seeking healthcare to be due to Campylobacter spp., Salmonella spp., norovirus and rotavirus<sup>8,9</sup>. Aetiology differs in SSA, with a meta-analysis amongst all ages identifying the main causative pathogens as Escherichia coli, Cryptosporidium, Cyclospora, Entamoeba and Shiqella spp. 10 There are several reasons for these differences in aetiology including different exposures and risk factors associated with poorer living conditions and poor underlying health. One important consideration is the high prevalence of human immunodeficiency virus (HIV) in SSA<sup>11</sup>. HIV is a known risk factor for diarrhoea, with episodes in HIV-infected individuals more likely to be severe, prolonged and result in hospitalisation with higher mortality rates than in HIV-uninfected individuals<sup>12,13</sup>. The aetiology of diarrhoea in HIV-infected individuals is known to shift with HIV disease progression and treatment<sup>14</sup>.

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

During early disease stages, while CD4+ counts are high and viral loads low, diarrhoea is often related to HIV seroconversion. As disease progresses, diarrhoea is frequently caused by opportunistic pathogens related to decreased immune function<sup>14</sup>. These pathogens include bacterial infections, such as Mycobacteria, parasitic infections, such as Cystoisospora belli, Cyclospora, Strongyloides, Cryptosporidia, Microsporidia and viral infections, such as cytomegalovirus (CMV)<sup>14–16</sup>. Patients with low CD4+ cell counts are at increased risk for chronic diarrhoea<sup>4</sup> and polyparasitic infection<sup>17</sup>. The HIV infection itself may be responsible for a proportion of the pathogen-negative cases, through HIV enteropathy and permanent damage to the gastrointestinal mucosa<sup>18</sup>, as well as changes in gut microbial populations leading to dysbiosis<sup>19</sup>. Mucosal damage reduces small bowel villous surface area, causing diarrhoea through malabsorption<sup>20</sup> as well as defects to cellular and humoral defence mechanisms in the gastrointestinal tract<sup>21</sup>. Pathogen-negative cases associated with advanced HIV disease may also be related to gastrointestinal tract involvement by Mycobacterium tuberculosis and/or avium<sup>22</sup> which is difficult to diagnose. A Dutch study found that 34% of diarrhoeal cases in untreated HIV-infected individuals could not be explained by a known causative agent, and hypothesized that these unexplained cases were due to the HIV-infection itself<sup>23</sup>. Initiation of antiretroviral treatment (ART), and accompanying increase in CD4+ cell count, is associated with a shift in the aetiology of diarrhoea from opportunistic infectious causes to noninfectious causes<sup>24</sup>. Data from both HICs and SSA show that although patients initiated on ART have significantly reduced diarrhoeal incidence compared with those not on treatment, the overall diarrhoeal incidence remains high<sup>18,25</sup>. A proportion of the remaining episodes in patients with wellcontrolled HIV may be drug-related<sup>18</sup>. There are limited aetiological data on HIV-related diarrhoeal diseases in SSA, with the majority of published studies focusing on children under the age of five years, with available data in older children and adults being limited by diagnostic technology<sup>14</sup>. A review of laboratory records in Botswana indicated that only 14% of stool specimens submitted for routine diagnostic testing for all ages had a pathogen detected, of which 8% were bacteria and 6% parasites<sup>26</sup>. Shigella spp. and

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

Salmonella spp. were the most commonly detected bacteria while Cystoisospora spp. and Cryptosporidium spp. were the most commonly detected parasites. Viral testing was not done. Although HIV status was not available for the participants in this analysis, Botswana is a high HIV prevalence setting with an estimated 23.9% of the population between 15-49 years old being HIVinfected during the study time period<sup>26</sup>. Contrary to these findings, a longitudinal cohort study of Zambian adults with a 31% HIV seroprevalence (higher than the estimated population HIV seroprevalence of 22%) found that pathogens could be detected in 99% of stool samples collected (diarrhoeal and non-diarrhoeal patients combined), with Cryptosporidium spp., Cystoisospora spp. and Citrobacter spp. being significantly more common in HIV-infected than HIV-uninfected individuals<sup>5</sup>. They found that HIV-infected adults in the pre-ART era were 2.4 times as likely to suffer from diarrhoea than HIV-uninfected adults and that this increased risk lasted throughout the infection rather than being limited to those with low CD4+ cell counts<sup>5</sup>. Meta-analysis data indicates a high burden of Cryptosporidium, microsporidia and Cystoisospora in SSA specifically<sup>16</sup>. Another recent meta-analysis identified South Africa as having the highest global Cryptosporidium prevalence (57.0%, CI 95%: 24.4-84.5%), although they recognised that these estimates were based on limited data<sup>27</sup>. A study in rural South Africa found that 60% of patients suffering from chronic diarrhoea were HIV-infected and that the majority of these infections were due to Campylobacter spp. (20%), Plesiomonas shiqelloides (17%), Aeromonas spp. (13%), Shiqella spp. (10%), Salmonella spp. (10%) and E. coli spp. (10%)<sup>28</sup>. Testing did not include parasites or viruses and results were not stratified by ART status. Other studies in African children have identified HIV-infection as a significant risk factor for rotavirus infection<sup>13,29</sup>. Very few studies in SSA in adults included screening for viruses, despite data from HICs showing that viruses (specifically norovirus and rotavirus) were responsible for as much as 44% of diarrhoea in adults presenting to emergency departments9. Patients with advanced HIV are at increased risk for diarrhoea due to CMV infection<sup>30</sup>. As CMV is mainly diagnosed on endoscopic biopsy<sup>31</sup>, prevalence is likely underestimated.

South Africa currently has the highest HIV burden in the world, representing 19% of the global HIV-infected population<sup>32</sup>. It is estimated that 86% of HIV-infected adults in South Africa have been diagnosed, with 57% of these on ART (50.8% - 72.7% by province)<sup>33</sup>. Women, elderly patients, those with inadequate access to WaSH facilities and those not yet initiated on ART, have the highest risk for developing diarrhoea amongst HIV-infected South Africans<sup>34</sup>. The majority of data on HIV-related diarrhoea comes from HICs with low HIV prevalence<sup>14</sup>. Since diarrhoeal aetiology is likely to vary between settings<sup>35</sup>, there is a need for more targeted epidemiological studies<sup>18</sup>, specifically in LMICs with high HIV prevalence. There are few studies in HIV-infected populations which investigate a

guidelines, especially since treatment is often based on guidelines rather than individual patient
diagnostics<sup>36</sup>. This study aimed to determine the pathogenic causes for diarrhoeal admissions in HIVinfected patients compared to controls without diarrhoea at three South African hospitals between

comprehensive range of pathogens or infections with multiple pathogens<sup>19</sup>. These data are

important for informing public health interventions and updating diagnostic and treatment

### Methods

Case and control enrolment

July 2018 and November 2021.

Patients of all ages hospitalised with diarrhoea were enrolled at Kalafong, Mapulaneng and Matikwana hospitals through the African Network for improved Diagnostics, Epidemiology and Management of common Infectious Agents (ANDEMIA)<sup>37</sup>. Kalafong Provincial Tertiary Hospital is based on the western outskirts of Pretoria (Gauteng Province) and serves the generally low-income communities residing in urban townships to the west of Pretoria<sup>38</sup>. The rural sites included Mapulaneng, a 180 bed district hospital, and Matikwana, a 250 bed regional hospital<sup>39</sup>, both located in Bushbuckridge district in Mpumalanga Province.

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

Cases were defined as patients admitted with diarrhoea (three or more loose or liquid stools over a 24 hour period) for any duration. Unmatched controls were defined as individuals presenting to the hospital or clinic for reasons other than diarrhoea (vaccination clinic, orthopaedic or surgical wards), without gastrointestinal symptoms (vomiting or diarrhoea) in the past 3 weeks. The study was explained to patients fulfilling the study definition and an information leaflet provided. Written informed consent was signed by patients ≥18 years of age and by parents/guardians for patients <18 years. An assent form was signed for patients between 7-17 years. Surveillance Officers completed investigation forms by interviewing the patient, parent/guardian and reviewing clinical notes and laboratory results where available. HIV status was determined from the clinical notes and available laboratory results. Stool specimens or rectal swabs were collected from both cases and controls. Patients were enrolled within 48 hours of admission to exclude nosocomial infections. Cases were enrolled from July 2018 to June 2021 and controls enrolled from October 2019 to November 2021. Cases and controls unable to provide specimens and patients <5 years old were excluded from this analysis. Laboratory testing Pathogen screening was performed on Fast-track Diagnostics (viral and bacterial gastroenteritis and stool parasite kits), Seegene Allplex (GI-Parasite and GI-Helminth(I) assays) as well as TaqMan Array Cards (TAC) (included pathogens indicated in Table S1). Monoplex PCR was used to determine final outcome where there were discrepant results between testing platforms for a specific target. Due to limited available TAC cards, cases with unknown HIV status were excluded from testing. Controls with unknown HIV status were included in the overall case-control analysis (since there were limited control specimens available) but were not included in the HIV specific case-control analysis. Data management and statistical analysis

Results for CD4+ cell count were extracted from the National Health Laboratory Service (NHLS)

database for HIV-infected cases and were categorised into three classes (<200 cells/µl; 200-500

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

cells/µl; >500 cells/µl). Only CD4+ cell count results within 12 months of the enrolment were included and where multiple results were available for a single patient, the results closest to the time of enrolment were used. Demographic and socioeconomic characteristics for cases and controls were compared. Clinical presentation for HIV-infected versus HIV-uninfected cases were compared. Pathogen detection amongst case and control specimens were compared, stratified by HIV status. Clinical presentation and pathogen detection for HIV-infected cases was compared between CD4+ cell count categories and for ART and cotrimoxazole prophylaxis treatment. X<sup>2</sup>-test and Fisher's exact test were used for categorical variables and t-test for continuous variables. P-values<0.05 were considered to be statistically significant. Stata software (version 14) was used for all analyses. Ethical considerations The ANDEMIA study was approved by the Human Research Ethics Committee (Medical) of the University of the Witwatersrand (approval numbers M170403) and the University of Pretoria Faculty of Health Sciences Research Ethics Committee (approval number 101/2017). The HIV sub-analysis was approved by the Human Research Ethics Committee (Medical) of the University of the Witwatersrand (approval numbers M190663). Results Enrolment and patient characteristics A total of 378 specimens for patients ≥5 years were collected during the study period, including 277 cases and 101 controls (Figure 1). Amongst cases, 164 (59.2%) were HIV-infected, 79 (28.5%) were HIV-uninfected and 34 (12.3%) had unknown HIV status. Amongst controls, 23 (22.8%) were HIVinfected, 50 (49.5%) were HIV-uninfected and 28 (27.7%) had unknown HIV status. Cases with unknown HIV status (n=34) were excluded (due to limited testing capacity), hence a total of 344 specimens were included in the analysis.

### Figure 1: Specimens included in the analysis

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

The median age of included patients was 34 years (IQR of 23-47), with cases being slightly older (median 36; IQR 26-51) than controls (median 31; IQR 17-38) (Table 1). The majority of patients were female (59.4%) and from the rural sites (67.4%), with proportionally more controls coming from the rural site than cases (82.2% versus 61.3%, p<0.001). Cases and controls were similar with respect to household crowding and dietary habits. Both cases and controls had good access to electric or gas cookers (86.1%), refrigerators (88.4%) and improved WaSH (94.8% access to improved water source and 96.4% access to private latrines/flush toilets). CD4+ cell counts were available for 99 (60.4%) of the 164 HIV-infected cases. Eight (8.1%) had counts >500 cells/µl, 21 (21.2%) were between 200-500 cells/µl and the majority (n=70, 70.7%) had <200 cells/µl. Information regarding ART was available for 156 (95.1%) of the HIV-infected cases, of which 130 (83.3%) were on treatment. Mean CD4+ cells counts were similar between those on ART (229.23 cells/μl) and those not on ART (169.7 cells/μl), (p=0.418). Information regarding cotrimoxazole treatment was available for 151 HIV-infected patients, of which 63 (41.7%) were on treatment.

Table 1: Comparison of patient characteristics for cases and controls

	Total (n=344)	Cases (n=243)	Controls (n=101)	<i>p</i> -value
Age (years) –	34 (23-47)	36 (26-51)	31 (17-38)	<0.001 <sup>f</sup>
median (IQR)				
Male	129 (40.6%)	88 (36.2%)	41 (40.6%)	0.445
Rural	232 (67.4%)	149 (61.3%)	83 (82.2%)	<0.001
HIV-infected <sup>a</sup>	187/316 (59.2%)	164/243 (67.5%)	23/73 (31.5%)	<0.001
Education <sup>b</sup>				
None	13/337 (3.9%)	10/237 (4.2%)	3/100 (3.0%)	0.002 g
<= 6 years	53/337 (15.7%)	47/237 (19.8%)	6/100 (6.0%)	
7-10 years	107/337 (31.8%)	78/237 (32.9%)	29/100 (29.0%)	
>10 years	164/337 (48.7%)	102/237 (43.0%)	62/100 (62.0%)	
Household	2.0 (1.2)	2.0 (1.9)	2.0 (0.9)	0.733 <sup>f</sup>
crowding/people				
per room – mean				
(std. dev)				
Electric or gas	296 (86.1%)	210 (86.4%)	86 (85.1%)	0.757
cooker				
Refrigerator	289/327 (88.4%)	200/231 (86.6%)	89/96 (92.7%)	0.115

perpetuity.

It is made available under a CC-BY 4.0 International license .

Improved water	326 (94.8%)	229 (94.2%)	97 (96.0%)	0.603 g
source <sup>c</sup>				
Treat drinking	45 (13.1%)	31 (12.8%)	14 (13.9%)	0.782
water <sup>d</sup>				
Toilet type				
Private flush	86/337 (25.5%)	62/241 (25.7%)	24/96 (25.0%)	0.604 g
Private latrine	239/337 (70.9%)	170/241 (70.5%)	69/96 (71.9%)	
Communal flush	8/337 (2.3%)	7/241 (2.9%)	1/96 (1.0%)	
Communal latrine	2/337 (0.6%)	1/241 (0.4%)	1/96 (1.0%)	
Other	2/337 (0.6%)	1/241 (0.4%)	1/96 (1.0%)	
Dairy <sup>e</sup>	156 (45.4%)	107 (44.0%)	49 (48.5%)	0.447
Deli meat <sup>e</sup>	103 (29.9%)	79 (32.5%)	24 (23.8%)	0.107
Eggs <sup>e</sup>	183 (53.2%)	127 (52.3%)	56 (55.5%)	0.590

<sup>&</sup>lt;sup>a</sup> For participants with known HIV status only; <sup>b</sup> highest level of education that the patient (or parent/caregiver if patient is <15 years) has obtained; <sup>c</sup> piped water to an inside or outside tap (as opposed to river, rain or well water or water from a truck); <sup>d</sup> by boiling or chemical treatment; <sup>e</sup> In the preceding 4 weeks; <sup>f</sup> t-test; <sup>g</sup> fisher's exact test; denominators given when different to column headings due to missing data.

### Clinical presentation of cases

HIV-infected cases were likely to experience symptoms for a longer duration before admission (median of 5 days versus 2 days, p<0.001) and were more likely to have chronic or persistent diarrhoea (8.5% versus 0.0%, p=0.006) than HIV-uninfected cases (Table 2). The most common symptoms experienced by all cases were fatigue (182, 74.9%), weight loss (176, 72.4%), vomiting (172, 70.8%), fever (168, 69.1%), abdominal pain (166, 68.3%) and nausea (165, 67.9%). HIV-infected cases were more likely to suffer from weight loss (81.1% versus 54.4%, p<0.001) and nausea (72.0% versus 59.5%, p=0.051), while HIV-uninfected cases were more likely to suffer from dysentery (15.2% versus 4.3%, p=0.003).

Table 2: Clinical presentation of diarrhoeal cases

	Total (n=243)	HIV-infected (n=164)	HIV-uninfected (n=79)	<i>p</i> -value
Duration of symptoms before admission (days) – median (IQR)	4 (2-8)	5 (3-8)	2 (1-4)	<0.001 <sup>d</sup>
Chronic/persistent diarrhoea <sup>a</sup>	13 (5.4%)	13 (7.9%)	0 (0.0%)	<b>0.011</b> <sup>e</sup>
Fatigue	182 (74.9%)	124 (75.6%)	58 (73.4%)	0.712
Weight loss	176 (72.4%)	133 (81.1%)	43 (54.4%)	<0.001
Vomiting	172 (70.8%)	118 (72.0%)	54 (68.4%)	0.564
Fever <sup>b</sup>	168 (69.1%)	113 (68.9%)	55 (69.6%)	0.910

perpetuity.

It is made available under a CC-BY 4.0 International license.

Abdominal pain	166 (68.3%)	106 (64.6%)	60 (76.0%)	0.076
Nausea	165 (67.9%)	118 (72.0%)	47 (59.5%)	0.051
Respiratory	105 (43.2%)	77 (47.0%)	28 (35.4%)	0.090
symptoms				
Headache	100 (41.2%)	68 (41.5%)	32 (40.5%)	0.887
Chills	63 (25.9%)	48 (29.3%)	15 (19.0%)	0.087
Arthralgia	51 (21.0%)	38 (23.2%)	13 (16.5%)	0.229
Dermatological	31 (12.8%)	25 (15.2%)	6 (7.6%)	0.094
symptoms				
Myalgia	24 (10.0%)	16 (9.8%)	8 (10.1%)	0.928
Dysentery <sup>c</sup>	19 (7.8%)	7 (4.3%)	12 (15.2%)	0.003
Neurological	10 (4.1%)	6 (3.7%)	4 (5.1%)	0.732 <sup>e</sup>
symptoms				
Painful	4 (1.7%)	3 (1.9%)	1 (1.3%)	>0.99 <sup>e</sup>
lymphadenopathy				

228 <sup>a</sup> diarrhoea for 28 days or longer; <sup>b</sup> current temperature of >38°C or history of fever in the past 10 days; <sup>c</sup> 229

Dysentery defined as self-reported blood in the stool; d t-test; e fisher's exact test

Pathogen detection in specimens of cases and controls

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

Pathogens were detected in 66.3% (228) of specimens tested, with significantly higher detection in cases compared with controls (72.8% versus 50.5%, p<0.001; Table 3). Bacteria were more prevalent in cases compared with controls (50.2% versus 28.7%, p<0.001), specifically Shigella spp., Salmonella spp. and Helicobacter pylori (24.3% versus 10.9%, p=0.005; 8.6% versus 1.0%, p=0.007 and 8.6% versus 0.0%, p=0.001, respectively). Detection of viruses was significantly higher in cases compared with controls (21.8% versus 10.9%, p=0.018), specifically for adenovirus (11.0% versus 4.0%, p=0.038). Parasites were detected in 37.8% (130) of specimens tested, however, detection was not significantly higher in cases than controls (40.7% versus 30.7%, p=0.080) with the available sample size. Prevalence of Cystoisospora, Cryptosporidium spp. and Enterocytozoon spp. was significantly higher in cases than controls (11.9% versus 0.0%, *p*<0.00; 11.1% versus 3.0%, *p*=0.012; 4.5% versus 0.0%, p=0.038, respectively). Blastocystis and Schistosoma were more prevalent amongst controls than amongst cases (23.8% versus 10.3%, p=0.001; 6.9% versus 2.1%, p=0.025, respectively). Cases were more likely than controls to have multiple pathogens detected (37.9% versus 22.8%, p=0.007). Amongst HIV-infected participants, Cystoisospora spp. prevalence was significantly higher in cases than in controls (17.7% versus 0.0%, p=0.028), while Schistosoma was detected more often in controls compared with cases (17.4% versus 2.4%, p=0.009). Amongst the HIV-uninfected

participants, *Shigella* spp., *Salmonella* spp. and *Helicobacter pylori* were more prevalent amongst cases than controls (36.7% versus 12.0%, p=0.002; 11.4% versus 0.0%, p=0.012; 10.1% versus 0.0%, p=0.023). Norovirus GII, *C. difficile*, *Campylobacter*, *Cystoisospora*, *Cryptosporidium* spp. and *Enterocytozoon* spp. were more prevalent amongst HIV-infected than HIV-uninfected participants (6.4% versus 1.6%, p=0.032; 7.0% versus 0.8%, p= 0.010; 6.4% versus 0.8%, p= 0.018; 15.5% versus 0.01%, p<0.001; 15.0% versus 1.6%, p<0.001; 5.4% versus 0.8%, p=0.031). *Shigella* spp. and *Blastocystis* were more prevalent amongst HIV-uninfected than HIV-infected participants (27.1% versus 17.1%, p=0.032; 25.6% versus 8.0%, p<0.001). *Shigella* spp. (18.3%) and *Cystoisospora* (17.7%) were the most prevalent pathogens detected in HIV-infected diarrhoeal cases, while *Shigella* spp. (36.7%) and *Salmonella* spp. (11.4%) were the most prevalent pathogens in HIV-uninfected diarrhoeal cases. Although *Blastocystis* was prevalent in HIV-uninfected cases, it was not associated with diarrhoea as prevalence was significantly higher in HIV-uninfected controls (40.0% versus 16.5%, p<0.001).

Table 3: Pathogen detection in specimens of cases and controls, stratified by HIV-infection status

	Overall – n	a (%)			HIV-infec	ted – na (%)	)		HIV-uninf	ected – na (9	6)		p-
	Total	Cases	Controls	p-	Total	Cases	Controls	<i>p</i> -	Total	Cases	Controls	p-	value <sup>c</sup>
	(n=344)	(n=243)	(n=101)	value <sup>b</sup>	(n=187)	(n=164)	(n=23)	value b	(n=129)	(n=79)	(n=50)	value <sup>b</sup>	
Any pathogen	228 (66.3)	177	51 (50.5)	<0.001	138	124	14 (60.9)	0.132	84 (65.1)	53 (67.1)	31 (62.0)	0.555	0.097
		(72.8)			(73.8)	(75.6)							
Virus	64 (18.6)	53 (21.8)	11 (10.9)	0.018	43 (22.1)	40 (24.4)	3 (13.0)	0.296 e	20 (15.5)	13 (16.5)	7 (14.0)	0.707	0.101
Adenovirus	31 (9.0)	27 (11.1)	4 (4.0)	<b>0.038</b> <sup>e</sup>	20 (10.7)	19 (11.6)	1 (4.4)	0.476 <sup>e</sup>	10 (7.8)	8 (10.1)	2 (4.0)	0.314 <sup>e</sup>	0.380
Adenovirus 40/41	3 (0.9)	3 (1.2)	0 (0.0)	0.558 <sup>e</sup>	2 (1.1)	2 (1.2)	0 (0.0)	>0.99 <sup>e</sup>	1 (0.8)	1 (1.3)	0 (0.0)	>0.99 <sup>e</sup>	0.637 <sup>e</sup>
Norovirus	18 (5.2)	14 (5.8)	4 (4.0)	0.603 e	13 (7.0)	13 (7.9)	0 (0.0)	0.374 <sup>e</sup>	5 (3.9)	1 (1.3)	4 (8.0)	0.074 <sup>e</sup>	0.246
Norovirus GI	4 (1.2)	2 (0.8)	2 (2.0)	0.584 e	1 (0.5)	1 (0.6)	0 (0.0)	>0.99 e	3 (2.3)	1 (1.3)	2 (4.0)	0.559 e	0.308 e
Norovirus GII	14 (4.1)	12 (4.9)	2 (2.0)	0.248 e	12 (6.4)	12 (7.3)	0 (0.0)	0.367 e	2 (1.6)	0 (0.0)	2 (4.0)	0.148 <sup>e</sup>	0.032 e
Enterovirus	16 (4.7)	12 (4.9)	4 (4.0)	0.787 <sup>e</sup>	12 (6.4)	10 (6.1)	2 (8.7)	0.645 e	4 (3.1)	2 (2.5)	2 (4.0)	0.641 e	0.296 <sup>e</sup>
CMV	3 (0.9)	3 (1.2)	0 (0.0)	0.558 e	3 (1.6)	3 (1.8)	0 (0.0)	>0.99 <sup>e</sup>	0 (0.0)	0 (0.0)	0 (0.0)	-	0.273 <sup>e</sup>
Astrovirus	5 (1.5)	4 (1.7)	1 (1.0)	>0.99 e	3 (1.6)	3 (1.8)	0 (0.0)	>0.99 <sup>e</sup>	2 (1.6)	1 (1.3)	1 (2.0)	>0.99 <sup>e</sup>	>0.99 e
Rotavirus	2 (0.6)	2 (0.8)	0 (0.0)	>0.99 e	1 (0.5)	1 (0.6)	0 (0.0)	>0.99 <sup>e</sup>	1 (0.8)	1 (1.3)	0 (0.0)	1.000 e	>0.99 <sup>e</sup>
Sapovirus	1 (0.3)	1 (0.4)	0 (0.0)	>0.99 <sup>e</sup>	1 (0.5)	1 (0.6)	0 (0.0)	>0.99 <sup>e</sup>	0 (0.0)	0 (0.0)	0 (0.0)	-	>0.99 <sup>e</sup>
>1 virus detected	9 (2.6)	7 (2.9)	2 (2.0)	>0.99 e	7 (3.7)	7 (4.3)	0 (0.0)	0.600 e	2 (1.6)	0 (0.0)	2 (4.0)	0.148 <sup>e</sup>	0.318 <sup>e</sup>
Bacteria	151 (48.9)	122	29 (28.7)	<0.001	87 (46.5)	76 (46.3)	11 (47.8)	0.894	61 (47.3)	46 (58.2)	15 (30.0)	0.002	0.894
		(50.2)											
Shigella spp.	70 (20.4)	59 (24.3)	11 (10.9)	0.005	32 (17.1)	30 (18.3)	2 (8.7)	0.378 <sup>e</sup>	35 (27.1)	29 (36.7)	6 (12.0)	0.002	0.032
Salmonella spp.	22 (6.4)	21 (8.6)	1 (1.0)	0.007 <sup>e</sup>	13 (7.0)	12 (7.3)	1 (4.4)	>0.99 <sup>e</sup>	9 (7.0)	9 (11.4)	0 (0.0)	0.012 <sup>e</sup>	0.993
C. difficile	14 (4.1)	13 (5.4)	1 (1.0)	0.074 <sup>e</sup>	13 (7.0)	12 (7.3)	1 (4.4)	>0.99 <sup>e</sup>	1 (0.8)	1 (1.3)	0 (0.0)	>0.99 <sup>e</sup>	<b>0.010</b> <sup>e</sup>
Campylobacter	13 (3.8)	12 (4.9)	1 (1.0)	0.119 <sup>e</sup>	12 (6.4)	12 (7.3)	0 (0.0)	0.367 e	1 (0.8)	0 (0.0)	1 (2.0)	0.388 e	<b>0.018</b> <sup>e</sup>
STEC	2 (0.6)	0 (0.0)	2 (2.0)	0.086 e	0 (0.0)	0 (0.0)	0 (0.0)	-	2 (1.6)	0 (0.0)	2 (4.0)	0.148 <sup>e</sup>	0.166 <sup>e</sup>
ETEC	11 (3.2)	9 (3.7)	2 (2.0)	0.519 <sup>e</sup>	7 (3.7)	5 (3.1)	2 (8.7)	0.207 e	4 (3.1)	4 (5.1)	0 (0.0)	0.157 e	>0.99 <sup>e</sup>
EPEC	21 (6.1)	14 (5.8)	7 (6.9)	0.631	15 (8.0)	11 (6.7)	4 (17.4)	0.094 e	6 (4.7)	3 (3.8)	3 (6.0)	0.676 e	0.237
EAEC	41 (11.9)	28 (11.5)	13 (12.9)	0.725	25 (13.4)	20 (12.2)	5 (21.7)	0.208	14 (10.9)	8 (10.1)	6 (12.0)	0.739	0.504
0157	4 (1.2)	4 (1.7)	0 (0.0)	0.325 <sup>e</sup>	3 (1.6)	3 (1.8)	0 (0.0)	>0.99 <sup>e</sup>	1 (0.8)	1 (1.3)	0 (0.0)	>0.99 <sup>e</sup>	0.648 <sup>e</sup>
Plesiomonas	1 (0.3)	1 (0.4)	0 (0.0)	>0.99 e	1 (0.5)	1 (0.6)	0 (0.0)	>0.99 <sup>e</sup>	0 (0.0)	0 (0.0)	0 (0.0)	-	>0.99 <sup>e</sup>
Helicobacter pylori	21 (6.1)	21 (8.6)	0 (0.0)	<b>0.001</b> e	13 (7.0)	13 (7.9)	0 (0.0)	0.374 <sup>e</sup>	8 (6.2)	8 (10.1)	0 (0.0)	0.023 <sup>e</sup>	>0.99

>1 bacteria	45 (13.1)	37 (15.2)	8 (7.9)	0.067	23 (12.3)	20 (12.2)	3 (13.0)	>0.99 e	11 (8.5)	8 (10.1)	3 (6.0)	0.528 e	0.287
detected	45 (15.1)	37 (13.2)	0 (7.5)	0.007	25 (12.5)	20 (12.2)	3 (13.0)	70.55	11 (0.5)	0 (10.1)	3 (0.0)	0.520	0.207
Parasite d	130 (37.8)	99 (40.7)	31 (30.7)	0.080	85 (45.5)	78 (47.6)	7 (30.4)	0.122	43 (33.3)	21 (26.6)	22 (44.0)	0.042	0.031
	` '	· · ·			` '	, ,	<u> </u>		· `	· · ·		0.042	-
Cystoisospora	29 (8.4)	29 (11.9)	0 (0.0)	<b>&lt;0.001</b> e	29 (15.5)	20 (17.7)	0 (0.0)	0.028 e	0 (0.0)	0 (0.0)	0 (0.0)	-	<b>&lt;0.001</b> e
Cryptosporidium	30 (8.7)	27 (11.1)	3 (3.0)	0.012 e	28 (15.0)	26 (15.9)	2 (8.7)	0.537 e	2 (1.6)	1 (1.3)	1 (2.0)	>0.99 <sup>e</sup>	<0.001
spp.													е
Blastocystis	49 (14.2)	25 (10.3)	24 (23.8)	0.001	15 (8.0)	12 (7.3)	3 (13.0)	0.403 <sup>e</sup>	33 (25.6)	13 (16.5)	20 (40.0)	0.003	<0.001
Giardia spp.	12 (3.5)	9 (3.7)	3 (3.0)	>0.99 <sup>e</sup>	7 (3.7)	7 (4.3)	0 (0.0)	0.600 e	4 (3.1)	2 (2.5)	2 (4.0)	0.641 e	>0.99 <sup>e</sup>
Enterocytozoon	11 (3.2)	11 (4.5)	0 (0.0)	0.038 e	10 (5.4)	10 (6.1)	0 (0.0)	0.614 e	1 (0.8)	1 (1.3)	0 (0.0)	>0.99 <sup>e</sup>	0.031 e
spp.													
Schistosoma	12 (3.5)	5 (2.1)	7 (6.9)	0.025	8 (4.3)	4 (2.4)	4 (17.4)	0.009 e	4 (3.1)	1 (1.3)	3 (6.0)	0.298 e	0.767 <sup>e</sup>
Dientamoeba	2 (0.6)	1 (0.4)	1 (1.0)	0.502 e	0 (0.0)	0 (0.0)	0 (0.0)	-	2 (1.6)	1 (1.3)	1 (2.0)	>0.99 <sup>e</sup>	0.166 <sup>e</sup>
>1 parasite	19 (5.5)	13 (5.4)	6 (5.9)	0.827	24 (12.8)	22 (13.4)	2 (8.7)	0.744 <sup>e</sup>	10 (7.8)	6 (7.6)	4 (8.0)	>0.99 <sup>e</sup>	0.152
detected													
Mixed infections	40 (11.6)	34 (14.0)	6 (5.9)	0.034		23 (14.0)	2 (8.7)	0.744 e	14 (10.9)	10 (12.7)	4 (8.0)	0.564 e	0.504
Virus-bacteria					25 (13.4)								
Virus-parasite	35 (10.2)	29 (11.9)	6 (5.9)	0.094	25 (13.4)	23 (14.0)	2 (8.7)	0.744 <sup>e</sup>	11 (8.5)	7 (8.9)	4 (8.0)	>0.99 <sup>e</sup>	0.183
Bacteria-parasite	72 (20.9)	60 (24.7)	12 (11.9)	0.008	46 (24.6)	41 (25.0)	5 (21.7)	0.734	23 (17.8)	16 (20.3)	7 (14.0)	0.366	0.152
>1 pathogen	115 (33.4)	92 (37.9)	23 (22.8)	0.007	73 (39.0)	66 (40.2)	7 (30.4)	0.366	40 (31.0)	26 (32.9)	14 (28.0)	0.557	0.143
detected													

<sup>a</sup>Total is 344 for overall analysis and 316 for the HIV analysis due to 28 controls with unknown HIV-status being excluded from the HIV analysis; <sup>b</sup>*p*-value comparing pathogen detection in cases versus controls (for HIV-infected and HIV-uninfected groups respectively); <sup>c</sup>*p*-value comparing pathogen detection in HIV-infected versus HIV-uninfected persons (cases and controls combined); <sup>d</sup> The following parasites were screened for but not detected: *Vibrio cholerae*, *Yersinia enterocolitica*, *E. histolytica*, *Strongyloides* spp., *Cyclospora*, *Hymenolepsis*, *Ascaris*, *Taenia*, *Trichuris*, *Ancylostoma*, *Enterobius*, *Necator*: <sup>e</sup> Fisher's exact test

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

Effect of CD4+ cell count and treatment on clinical presentation and pathogen detection amongst HIV-infected diarrhoeal cases For HIV-infected cases, presentation did not differ by CD4+ cell count for duration of symptoms, fever, vomiting, fatigue, nausea, respiratory symptoms, abdominal pain, dermatological symptoms, chills, headache, dysentery, arthralgia, myalgia, neurological symptoms or painful lymphadenopathy (Table S2). There was an increased proportion of cases reporting weight loss with lower CD4+ cell counts (91.4%, 81.0% and 62.5% for CD4+ cell counts of <200, 200-500, >500 cells/mm<sup>3</sup> respectively; p=0.032). Pathogens were detected more frequently in cases with low CD4+ cell counts (75.7%, 42.9% and 37.5% for CD4+ cell counts of <200, 200-500, >500 cells/mm<sup>3</sup> respectively; p=0.004) (Table S3). Cryptosporidium spp. specifically, was detected more often in those with low CD4+ cell counts (25.7%, 4.8% and 0.0% for CD4+ cell counts of <200, 200-500, >500 cells/mm<sup>3</sup> respectively; p=0.039). Clinical presentation was similar amongst HIV-infected cases on ART and those not on ART (Table S4). Those on cotrimoxazole prophylaxis were more likely to experience fatigue (88.9% versus 69.3%, p=0.005), weight loss (90.5% versus 76.1%, p=0.023) and chills (50.8% versus 15.9%, p<0.001) then those not on cotrimoxazole. Pathogen detection was similar amongst HIV-infected cases on ART and those not on ART (72.3% versus 88.5%, p=0.082) (Table S5). Parasites, specifically *Cystoisospora* spp. were more commonly detected amongst patients on cotrimoxazole compared with those not on cotrimoxazole (27.0% versus 11.4%, p=0.014). Other pathogens were found in similar proportions across treatment groups. Clostridioides difficile detection C. difficile was detected in 14 cases, 13 of which were in HIV-infected patients (92.9%). Symptoms were similar between cases in which C. difficile was detected and those without C. difficile detection, however those with C. difficile detected were more likely to have had a longer duration of illness before admission (6.5 (IQR 4-11) days versus 4 (IQR 2-7) days) (data not shown). It is important to

distinguish *C. difficile* colonisation from disease to avoid unnecessary antimicrobial therapy. The case definition, as per the guidelines for diagnostic and clinical management of *C. difficile* from the South African Society for Clinical Microbiology, includes onset of diarrhoea more than 48 hours after admission, or diarrhoea that continues for 3 days post admission and where there is no likely alternatively cause (no other pathogens detected or use of laxatives), or where the patient has had an admission or antibiotics use in the past 12 weeks. <sup>40</sup> Three of the 14 cases did not match this case definition as they did not have an admission in the past 12 weeks and had multiple pathogens detected on PCR. These three cases were however HIV-infected. Five of the cases had no other pathogens detected on PCR, all of which were HIV-infected. Eight of the cases did have a prior admission, however the majority of these (n=6, 75.0%) had multiple pathogens detected on PCR. In addition, the guidelines recommend that specimens testing positive for *C. difficile* on PCR (which is highly sensitive for detection of *C. difficile*), should have further toxins A/B immunoassays performed (which have high specificity for diagnosis of *C. difficile* infection). This was not done in the current analysis.

# Discussion

Despite advances in HIV treatment, diarrhoea amongst HIV-infected patients remains a significant public health challenge<sup>19</sup>. Our study found that the majority (67.5%) of patients 5 years and older with known HIV-status admitted to the study sites with diarrhoea were HIV-infected, highlighting the importance of HIV-related illnesses among South African adults hospitalised with diarrhoea. The Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 treatment target aims to ensure that 90% of the HIV-infected population are diagnosed, 90% of those diagnosed are initiated on ART and 90% of those on ART should achieve viral suppression<sup>41</sup>. A recent South African analysis estimated that 70.7% of diagnosed HIV-infected individuals have initiated ART, and 87.4% of these are thought to be virally suppressed<sup>41</sup>. Proportions reported in the current analysis reflect these numbers, as 83.3% of HIV-infected patients with known ART status were on treatment, however a

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

large proportion of HIV-infected patients included in this analysis had CD4+ cell count <200 cells/μl (70/99, 70.7%) indicating that they are unlikely to be virally suppressed. Mpumalanga (home province to the majority of the patients included in this analysis) is the only South African province in which the third-90 indicator value (the percentage of those on ART that are virally suppressed) is below 85%<sup>41</sup>. It is also likely that the study design was skewed towards detection of poorly suppressed HIV cases as they are most likely to be hospitalised for diarrhoea. Diarrhoea in patients with viral suppression will likely be seen at a clinic level. Further studies at clinic level are recommended in order to include a broader spectrum of cases. The clinical presentation of diarrhoea in HIV-infected cases differs to that of HIV-uninfected cases. HIV-infected diarrhoeal cases were more likely to have symptoms for a longer duration before admission and to suffer from weight loss and nausea. HIV-uninfected cases were more likely to suffer from dysentery. This finding has not been reported in other studies, however it is likely related to aetiological differences between HIV-infected and HIV-uninfected diarrhoeal patients. Amongst HIV-infected cases, patients on cotrimoxazole were more likely to experience fatigue, weight loss and chills and were more likely to have parasites detected, specifically *Cystoisospora* spp., compared to those not on cotrimoxazole. This is an interesting finding since cotrimoxazole is the prescribed treatment for this pathogen. Since all patients with CD4+ <200 cells/µl should receive cotrimoxazole prophylaxis, it can be used as a surrogate marker for advanced HIV disease. However this finding may also point to changes in Cystoisospora sensitivity for cotrimoxazole or may indicate that these patients are carriers or take longer to clear the pathogen. The possibility of drug resistance should be further investigated in future studies. The use of molecular methods and the expanded panel of pathogens included in testing resulted in a high pathogen detection rate, with pathogen detection being significantly higher in cases compared with controls. Although viruses were commonly detected (18.5% of all specimens tested) and were more likely to be detected in cases as compared with controls, when stratified by HIV status, viruses were not significantly associated with diarrhoea in this study. Although this lack of association may

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

be partly due to asymptomatic carriage of viruses (specifically in HIV-uninfected patients), it is likely that the sample size was insufficient to determine significant differences between cases and controls when stratified by HIV status. Interestingly, norovirus GII was more prevalent in HIV-infected individuals than HIV-uninfected individuals and detection in HIV-infected individuals was limited to cases. Previous findings from South Africa have shown that HIV-infected children are more likely to suffer poor outcomes related to norovirus infection<sup>42</sup>, however detection rates were similar amongst HIV-infected and –uninfected children. This increased detection of norovirus in HIV-infected patients ≥5 years of age has not been previously described. Bacteria was detected in 43.9% of specimens tested and was significantly associated with diarrhoea overall and amongst HIV-uninfected patients. Interestingly, prevalence of bacterial pathogens was high in both cases and controls within the HIVinfected group. This was specifically due to the high prevalence of E. coli spp. (including ETEC, EPEC and EAEC) amongst HIV-infected controls. High E. coli spp. colonisation rates in HIV-infected patients have been documented in other settings<sup>43</sup>. We found Shiqella spp, Salmonella spp. and H. pylori to be significantly associated with diarrhoea in the current study, specifically amongst HIVuninfected patients. It's likely that the sample size was insufficient to detect a difference in prevalence between cases and controls in the HIV-uninfected group. Campylobacter spp. and C. difficile were detected more often in HIV-infected patients as compared with HIV-uninfected patients but were not significantly associated with diarrhoea (likely due to small sample sizes). As expected from literature<sup>14</sup>, parasite prevalence was significantly higher amongst HIV-infected compared with HIV-uninfected patients, specifically Cystoisospora, Cryptosporidium spp. and Enterocytozoon spp., although only Cystoisospora was significantly associated with diarrhoea amongst HIV-infected patients. The case-control analysis indicated that Blastocystis and Schistosoma are unlikely to be causative agents of diarrhoea since these pathogens were detected at higher rates in controls than in cases. Prevalence of Schistosoma among healthy individuals has been reported to be as high as 51.2% in the Democratic Republic of Congo and is likely to be higher in villages and rural areas where water is collected from rivers and dam<sup>44</sup>. Blastocystis has been noted as an

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

important cause of diarrhoea amongst immunosuppressed patients<sup>45</sup>, however this was not found in the current study. Diarrhoeal aetiology differed with HIV status, with Shigella spp. and Salmonella spp. being prevalent amongst HIV-uninfected cases and Shigella spp., Cystoisospora, and Cryptosporidium spp. being prevalent amongst HIV-infected cases. These differences should be considered during development of diagnostic and treatment guidelines. This study highlights the importance of Shiqella spp. in diarrhoeal morbidity amongst adults (regardless of HIV status). According to the Global Burden of Disease Study (GBD), Shiqella spp. were the leading cause of diarrhoeal deaths amongst individuals over the age of 5 years and the second leading cause of death in young children in 2016<sup>1</sup>. While there is currently no approved Shigella vaccine, there are several candidates which show promise for efficacy testing<sup>46</sup>. In order to introduce a candidate vaccine, burden estimates are required. Although a larger sample size is required, this analysis gives an indication of the high burden of Shigella spp. in our setting. Further work is required to determine if HIV-infected individuals should be considered as a risk group for possible target should Shigella vaccine become available. Our results are in line with clinical literature which indicates a shift in diarrhoeal aetiology with CD4+ cell count amongst HIV-infected patients. Pathogen detection was high in those with CD4+ cell counts <200 cells/μl, indicating increased opportunistic infections (specifically *Cryptosporidium* spp.). Pathogens could only be detected in just over a third of cases with high CD4+ cell count (>500 cells/µl), suggesting that these cases are possibly drug-related. This finding may be useful for treatment guidelines. It also highlights the importance of addressing diarrhoea in patients on ART especially since chronic diarrhoea has been identified as an major cause of dropout from ART care services<sup>47</sup>. Detection of *C. difficile* in this study was almost exclusive to HIV-infected participants (13/14, 92.9%; including 12 cases and 1 control). Data from another hospital study in Gauteng Province estimated that community acquired C. difficile infections represent only 1.3% of cases (with the remaining

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

98.7% being hospital acquired)<sup>48</sup>. Our study design excluded cases of hospital-acquired diarrhoea, as enrolment and specimen collection was done within 48 hours of admission. The 5.4% C. difficile prevalence reported here is lower than systematic review estimates of 15.8% amongst symptomatic non-immunosuppressed in-patients from LMIC<sup>49</sup>. This systematic review indicated similar rates amongst immunosuppressed and non-immunosuppressed populations<sup>49</sup> whereas the current study found that C. difficile was more commonly detected in HIV-infected cases than in –uninfected cases. While not considered an opportunistic infection, C. difficile is associated with exposure to healthcare settings and with the use of antibiotics, both of which are increased amongst HIV-patients<sup>50</sup>. The increased management of HIV patients in an outpatient setting<sup>51</sup> may dispute the inclusion of recent admission as a criterion in the case definition. There is also growing evidence to suggest the possibility of C. difficile being an important community-acquired pathogen<sup>51</sup>, and consideration of this should be given in populations with high HIV prevalence. A major limitation of this study was the small sample size which restricted the analysis (attributable fractions and odds ratios could not be calculated as many categories had zero count). The ANDEMIA study was not specifically aimed at enrolling HIV-infected cases and controls, therefore this analysis relied on incidental HIV enrolments. Enrolment, specifically of controls, was also hampered by COVID-19 restrictions. An extension of this analysis would benefit from enrolling controls from HIV clinics. Viral load was not analysed here, since few recent results were available; thus recent CD4+ cell count was used as a proxy. CD4+ cell counts were not available for all HIV-infected cases at the time of admission. Many of those without CD4+ cell counts available were matched from NHLS data, however these tests were not always performed at the same time as the enrolment. We used a cut off of 12 months on either side of enrolment for CD4+ cell counts as this was deemed to be a reasonable estimation of the CD4+ cell count at admission. In cases where there were significant changes in CD4+ cell counts over time, these may have been incorrectly quantified. There were also limited data available for antibiotic use. Date of last dose was available, however start date for antibiotic course was not collected. This has limitations specifically for the C. difficile analysis, since

we could not determine the length of antibiotic courses. Future studies should also investigate the expansion of diagnostic testing for *M. avium* which was not done in the present study. In conclusion, this study highlights the importance of HIV-related diarrhoea amongst South African inpatients ≥5 years of age, and underscores the importance of research in a high HIV prevalence setting in order to improve the understanding of aetiology of diarrhoea. These data are important for development of guidelines and treatment protocols as well as for preventative interventions, such as vaccine introduction. Our data specifically highlights the importance of Shiqella spp. amongst both HIV-infected and HIV-uninfected diarrhoeal patients. We suggest that research be expanded to primary healthcare levels in order to include a broader spectrum of HIV disease, specifically to investigate diarrhoea in individuals with well-controlled HIV. **Acknowledgments** We wish to acknowledge the ANDEMIA participants, funders, staff and clinical staff at the hospitals. Thank you to Ann Christin Vietor for statistical assistance.

References:


440

441 1. Troeger C, Blacker BF, Khalil IA, Rao PC, Cao S, Zimsen SR, et al. Estimates of the global, 442 regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 443 444 2018;18(11):1211-28. 2. Fischer Walker CL, Black RE. Diarrhoea morbidity and mortality in older children, adolescents, 445 and adults. Epidemiol Infect. 2010;138:1215-26. 446 3. 447 Farthing M, Salam MA, Lindberg G, Dite P, Khalif I, Salazar-Lindo E, et al. Acute diarrhea in adults and children: A global perspective. J Clin Gastroenterol. 2013;47(1):12-20. 448 449 4. Dwivedi K, Prasad G, Saini S, Mahajan S, Lal S, Baveja U. Enteric opportunistic parasites among HIV infected individuals: associated risk factors and immune status. Jpn J Infect Dis. 450 2007;60:76-81. 451 452 5. Kelly P, Todd J, Sianongo S, Mwansa J, Sinsungwe H, Katubulushi M, et al. Susceptibility to 453 intestinal infection and diarrhoea in Zambian adults in relation to HIV status and CD4 count. BMC Gastroenterol. 2009;9(7). 454 6. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H. A comparative risk 455 456 assessment of burden of disease and injury attributable to 67 risk factor clusters in 21 457 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859). 458 7. Grace D. Food safety in low and middle income countries. Int J Environ Res Public Heal. 459 2015;12:10490-507. 460 8. Jansen A, Stark K, Kunkel J, Schreier E, Ignatius R, Liesenfeld O, et al. Aetiology of community-461 acquired, acute gastroenteritis in hospitalised adults: a prospective cohort study. BMC Infect 462 463 Dis. 2008;8(1):1-7.

464 9. Bresee JS, Marcus R, Venezia RA, Keene WE, Morse D, Thanassi M, et al. The etiology of 465 severe acute gastroenteritis among adults visiting emergency departments in the United 466 States. J Infect Dis. 2012;205(9):1374-81. 10. Fletcher S, Stark D, Ellis J. Prevalence of gastrointestinal pathogens in Sub-Saharan Africa: 467 468 systematic review and meta-analysis. J Public Heal Africa. 2011;2(2). Joint United Nations Programme on HIV/AIDS (UNAIDS). The Gap Report [Internet]. 2014. 469 11. 470 Available from: https://unaidstest.unaids.org/sites/default/files/unaids/contentassets/documents/unaidspublication/2014/ 471 472 UNAIDS\_Gap\_report\_en.pdf 473 12. Germani Y, Minssart P, Vohito M, Yassibanda S, Glaziou P, Hocquet D, et al. Etiologies of 474 acute, persistent, and dysenteric diarrheas in adults in Bangui, Central African Republic, in 475 relation to human immunodeficiency virus serostatus. Am J Trop Med Hyg. 2017;59(6):1008-14. 476 Acácio S, Nhampossa T, Quintó L, Vubil D, Sacoor C, Kotloff K, et al. The role of HIV infection 477 13. in the etiology and epidemiology of diarrheal disease among children aged 0-59 months in 478 Manhiça District, Rural Mozambique. Int J Infect Dis. 2018;73:10–7. 479 480 14. Feasey NA, Healey P, Gordon MA. Review article: the aetiology, investigation and 481 management of diarrhoea in the HIV-positive patient. Aliment Pharmacol Ther. 2011;34:587-603. 482 483 15. Thomas P, Pollok R, Gazzard B. Enteric viral infections as a cause of diarrhoea in the acquired immunodeficiency syndrome. HIV Med. 1999;1:19-24. 484 485 16. Wang Z, Liu Q, Liu H, Li S, Zhang L, Zhao Y, et al. Prevalence of Cryptosporidium, microsporidia 486 and Isospora infection in HIV-infected people: a global systematic review and meta-analysis. 487 Parasites and Vectors. 2018;11(28).

- 488 17. Vyas N, Pathan N, Aziz A. Enteric pathogens in HIV-positive patients with diarrhoea and their correlation with CD4+ T-lymphocyte counts. Trop Parasitol. 2012;2(1):29-34.
- 490 18. Asmuth D, Clay P, Blick G, Chaturvedi P, MacFarlane K. Incidence and prevalence of diarrhoea
- 491 in HIV clinical trials in the recent post-cART era: analysis of data from 38 clinical trials from
- 492 2008-2017 over 21,000 patients. In: 22nd International AIDS Conference. Amsterdam; 2018.
- 493 19. Logan C, Beadsworth M, Beeching N. HIV and diarrhoea: what is new? Curr Opin Infect Dis.
- 494 2016;29(5):486-94.

- 495 20. Harris E, Washington K. Manifestations of immunodeficiency in the GI tract. In: Odze R,
- Goldblum J, editors. Surgical pathology of the GI tract, liver, biliary tract, and pancreas 496
- 497 (Second edition). 2nd ed. Elsevier Inc.; 2009. p. 81-96.
- Awole M, Gebre-Selassie G, Kassa T, Kibru G. Isolation of potential bacterial pathogens from 498 21.
- 499 the stool of HIV-infected and HIV-non-infected patients and their antimicrobial susceptibility
- 500 patterns in Jimma Hospital, South West Ethiopia. Ethiop Med J. 2002;40:353-64.
- 501 22. Dikman AE, Schonfeld E, Srisarajivakul NC, Poles MA. Human Immunodeficiency Virus-
- 502 Associated Diarrhea: Still an Issue in the Era of Antiretroviral Therapy. Dig Dis Sci.
- 503 2015;60(8):2236-45.
- 504 23. Oude Munnink B, Canuti M, Deijs M, de Vries M, Jebbink M, Rebers S, et al. Unexplained
- 505 diarrhoea in HIV-1 infected individuals. BMC Infect Dis. 2014;14(22).
- 506 24. Call S, Heudebert G, Saag M, Wilcox C. The changing etiology of chronic diarrhea in HIV-
- 507 infected patients with CD4 cell counts less than 200 cells/mm3. Am J Gastroenterol.
- 508 2000;95(11):3142-6.
- 509 25. Rubaihayo J, Tumwesigye N, Konde-Lule J, Wamani H, Nakku-Joloba E, Makumbi F. Frequency
- 510 and distribution patterns of opportunistic infections associated with HIV/AIDS in Uganda.
- 511 BMC Res Notes. 2016;9(1).



535 35. Elfstrand L, Floren C. Management of chronic diarrhea in HIV-infected patients: current 536 treatment options, challenges and future directions. HIV AIDS. 2010;2:219-24. 36. 537 Riddle MS, Dupont HL, Connor BA. ACG clinical guideline: Diagnosis, treatment, and 538 prevention of acute diarrheal infections in adults. Am J Gastroenterol. 2016;111(5):602–22. 539 37. Schubert G, Achi V, Ahuka S, Belarbi E, Bourhaima O, Eckmanns T, et al. The African Network for Improved Diagnostics, Epidemiology and Management of common infectious Agents. 540 BMC Infect Dis. 2021;21(1):539. 541 542 38. Delport S, Swanepoel J, Odendaal P, Roux P. Incidence of retinopathy of prematurity in verylow-birth-weight infants born at Kalafong Hospital, Pretoria. South African Med J. 543 544 2002;92(12):986-90. Msimang VMY, Page N, Groome MJ, Moyes J, Cortese MM, Seheri M, et al. Impact of 545 39. rotavirus vaccine on childhood diarrheal hospitalization after introduction into the South 546 African Public Immunization Program. Pediatr Infect Dis J. 2013;32(12):1359-64. 547 548 40. Nana T, Moore C, Boyles T, Brink AJ, Cleghorn J, Devenish LM, et al. South African Society of Clinical Microbiology Clostridioides difficile infection diagnosis, management and infection 549 550 prevention and control guideline. South African J Infect Dis. 2020;35(1). 551 41. Marinda E, Simbayi L, Zuma K, Zungu N, Moyo S, Kondlo L, et al. Towards achieving the 90-552 90–90 HIV targets: Results from the South African 2017 national HIV survey. BMC Public 553 Health. 2020;20(1):1-12. 554 42. Page NA, Groome MJ, Nadan S, Netshikweta R. Norovirus epidemiology in South African children <5 years hospitalised for diarrhoeal illness between 2009 and 2013. Epidemiol Infect. 555 556 2017; 557 43. Garcia C, Chincha O, Leon M, Iglesias D, Barletta F, Mercado E, et al. Short Report: High 558 Frequency of Diarrheagenic Escherichia coli in Human Immunodeficiency Virus (HIV) Patients

559 with and without Diarrhea in Lima, Perú. Am J Trop Med Hyg. 2010;82(6):1118–20. 560 44. Madinga J, Id LM, Barbe B, Linsuke S, Hermy M, Heroes A, et al. Non-typhoidal Salmonella 561 intestinal carriage in a Schistosoma mansoni endemic community in a rural area of the Democratic Republic of Congo. PLoS Negl Trop Dis. 2020;14(10):e0007875. 562 563 45. Rao K, Sekar U, Iraivan KT, Abraham G, Soundararajan P. Blastocystis hominis — An Emerging 564 Cause of Diarrhoea in Renal Transplant Recipients. J Assoc Physicians India. 2003;51:719–21. 565 46. Hosangadi D, Smith PG, Giersing BK. Considerations for using ETEC and Shigella disease 566 burden estimates to guide vaccine development strategy. Vaccine. 2019;37(50):7372-80. 567 47. Asiimwe SB, Kanyesigye M, Bwana B, Okello S, Muyindike W. Predictors of dropout from care among HIV-infected patients initiating antiretroviral therapy at a public sector HIV treatment 568 clinic in sub-Saharan Africa. BMC Infect Dis. 2016;16(43). 569 570 48. Godinho L, Feldman C. Clostridium difficile infection in Johannesburg, South Africa. Hosp 571 Pract. 2018;46(5):287-94. 572 49. Forrester JD, Cai LZ, Mbanje C, Rinderknecht TN, Wren SM. Clostridium difficile infection in 573 low- and middle-human development index countries: a systematic review. Trop Med Int 574 Heal. 2017;22(10):1223-32. 575 50. Revolinski SL. Munoz-Price LS. Clostridium difficile in Immunocompromised Hosts: A Review 576 of Epidemiology, Risk Factors, Treatment, and Prevention. Clin Infect Dis. 2019;68(12):2144– 577 53. Collini PJ, Kuijper E, Dockrell DH. Clostridium Difficile Infection in Patients with HIV/AIDS. Curr 578 51. 579 HIV/AIDS Rep. 2013;10:273-82. 580

# **Supplementary tables:**

582

583

# Table S1: Pathogens included in molecular testing

Pathogen	Testing platform				
Viruses					
Norovirus GI	FTD viral gastroenteritis, TaqMan Array Cards				
Norovirus GII	FTD viral gastroenteritis, TaqMan Array Cards				
Human astrovirus	FTD viral gastroenteritis, TaqMan Array Cards				
Rotavirus	FTD viral gastroenteritis, TaqMan Array Cards				
Human adenovirus	FTD viral gastroenteritis, TaqMan Array Cards				
Sapovirus	FTD viral gastroenteritis, TaqMan Array Cards				
Enterovirus	TagMan Array Cards				
CMV	Monoplex PCR				
Bacteria					
Campylobacer coli/jejuni/lari	FTD bacterial gastroenteritis, TaqMan Array Cards				
Clostridioides difficile	FTD bacterial gastroenteritis, TaqMan Array Cards				
Escherichia coli verotoxin positives	FTD bacterial gastroenteritis				
Salmonella spp.	FTD bacterial gastroenteritis, TaqMan Array Cards				
Shigella spp.	FTD bacterial gastroenteritis, TaqMan Array Cards				
Enteroinvasive <i>Escherichia coli</i>	FTD bacterial gastroenteritis, TaqMan Array				
Yersinia enterocolitica	FTD bacterial gastroenteritis, TaqMan Array Cards				
EAEC	TagMan Array Cards				
EPEC	TaqMan Array Cards				
ETEC	TaqMan Array Cards				
STEC/VTEC	FTD bacterial gastroenteritis; TaqMan Array Cards				
E. coli 0157	TaqMan Array Cards				
Parasites					
Plesiomonas shigelloides	TaqMan Array Cards				
Entamoeba histolytica	FTD enteric parasites, TaqMan Array Cards, SeeGene Allplex				
Cryptosporidium spp.	FTD enteric parasites, TaqMan Array Cards, SeeGene Allplex				
Giardia lamblia	FTD enteric parasites, TaqMan Array Cards, SeeGene Allplex				
Vibrio cholerae	TaqMan Array Cards				
Helicobacter pylori	TaqMan Array Cards				
Schistosoma	TaqMan Array Cards				
Enterocytozoon spp.	TaqMan Array Cards, SeeGene Allplex				
Strongyloides stercoralis	TagMan Array Cards, SeeGene Allplex				
Cytoisospora belli	TagMan Array Cards				
Blastocystis hominis	SeeGene Allplex				
Dientamoeba fragilis	SeeGene Allplex				
Cyclospora cayentanensis	SeeGene Allplex				
Hymenolepsis nana	SeeGene Allplex				

Ascaris lumbricoides	SeeGene Allplex
Taenia spp.	SeeGene Allplex
Trichuris trichiura	SeeGene Allplex
Ancylostoma duodenale	SeeGene Allplex
Enterobius vermicularis	SeeGene Allplex
Necator americanus	SeeGene Allplex

## Table S2: Clinical presentation for HIV-infected cases, stratified by CD4+ cell counts

	CD4+ cell count <sup>a</sup>			<i>p</i> -value
	<200 cells/μl	200-500 cells/μl	>500 cells/µl	
	(n=70)	(n=21)	(n=8)	
Duration of	6 (3-10)	7 (3.5-12)	5.5 (3-7)	0.822
symptoms before				
admission – median				
(IQR)				
Chronic/persistent	6 (8.6%)	2 (9.5%)	1 (12.5%)	0.855
diarrhoea				
Weight loss	64 (91.4%)	17 (81.0%)	5 (62.5%)	0.032
Fatigue	58 (82.9%)	16 (76.2%)	5 (62.5%)	0.293
Nausea	6 (75.0%)	15 (71.4%)	6 (75.0%)	>0.99
Vomiting	48 (68.6%)	14 (66.7%)	6 (75.0%)	>0.99
Fever (current or	46 (65.7%)	14 (66.7%)	5 (62.5%)	>0.99
history)				
Abdominal pain	41 (58.6%)	14 (66.7%)	4 (50.0%)	0.667
Respiratory	33 (47.1%)	12 (57.1%)	1 (12.5%)	0.097
symptoms				
Chills	32 (45.7%)	7 (33.3%)	3 (37.5%)	0.634
Headache	32 (45.7%)	7 (33.3%)	4 (50.0%)	0.635
Dermatological	13 (18.6%)	3 (14.3%)	0 (0.0%)	0.494
symptoms				
Arthralgia	11 (15.7%)	6 (28.6%)	0 (0.0%)	0.171
Myalgia	11 (15.7%)	1 (4.8)%	0 (0.0%)	0.334
Neurological	5 (7.1%)	0 (0.0%)	1 (12.5%)	0.347
symptoms				
Dysentery <sup>b</sup>	2 (2.9%)	0 (0.0%)	0 (0.0%)	>0.99
Painful swollen glands	2 (2.9%)	0 (0.0%)	0 (0.0%)	>0.99

<sup>&</sup>lt;sup>a</sup> CD4+ count within 12 months of enrolment only known for 99 of the 164 HIV-infected patients included in molecular testing; <sup>b</sup> Dysentery defined as self-reported blood in the stool.

## Table S3: Pathogen detection in specimens of HIV-infected cases, stratified by CD4+ cell count

595

596

597

598

	CD4+ count a - n (%)			<i>p</i> -value
	>500 cells/µl (n=8)	200-500 cells/μl (n=21)	<200 cells/μl (n=70)	,
Any pathogen	5 (62.5)	12 (57.1)	59 (84.3)	0.022
Virus	2 (25.0)	5 (23.8)	19 (27.1)	>0.99
Adenovirus	0 (0.0)	5 (23.8)	8 (11.4)	0.170
Adenovirus 40/41	0 (0.0)	1 (4.8)	0 (0.0)	0.293
Norovirus	0 (0.0)	1 (4.8)	6 (8.6)	>0.99
Norovirus GI	0 (0.0)	0 (0.0)	0 (0.0)	-
Norovirus GII	0 (0.0)	1 (4.8)	6 (8.6)	>0.99
Enterovirus	2 (25.0)	0 (0.0)	7 (10.0)	0.068
CMV	0 (0.0)	0 (0.0)	2 (2.9)	>0.99
Astrovirus	0 (0.0)	0 (0.0)	2 (2.9)	>0.99
Rotavirus	0 (0.0)	0 (0.0)	1 (1.4)	>0.99
Sapovirus	0 (0.0)	0 (0.0)	1 (1.4)	>0.99
>1 virus detected	0 (0.0)	1 (4.8)	5 (7.1)	>0.99
Bacteria	4 (50.0)	8 (38.1)	35 (50.0)	0.638
Shigella spp.	1 (12.5)	1 (4.8)	12 (17.1)	0.389
Salmonella spp.	0 (0.0)	0 (0.0)	7 (10.0)	0.322
C. difficile	0 (0.0)	1 (4.8)	9 (12.9)	0.450
Campylobacter		0 (0.0)	4 (5.7)	0.695
STEC	0 (0.0)	0 (0.0)	0 (0.0)	-
ETEC	0 (0.0)	0 (0.0)	2 (2.9)	>0.99
EPEC	0 (0.0)	0 (0.0)	6 (8.6)	0.464
EAEC	1 (12.5)	4 (19.1)	8 (11.4)	0.622
0157	0 (0.0)	0 (0.0)	2 (2.9)	>0.99
Plesiomonas	0 (0.0)	1 (4.8)	0 (0.0)	0.293
Helicobacter pylori	1	2 (9.5)	4 (5.7)	0.109
>1 bacteria detected	0 (0.0)	1 (4.8)	14 (20.0)	0.131
Parasite <sup>b</sup>	2 (25.0)	8 (38.1)	39 (55.7)	0.145
Cystoisospora	1 (12.5)	4 (19.1)	12 (17.1)	>0.99
Cryptosporidium	0 (0.0)	1 (4.8)	19 (27.1)	0.028
spp.				
Blastocystis	1 (12.5)	2 (9.5)	5 (7.1)	0.563
Giardia spp.	0 (0.0)	1 (4.8)	4 (5.7)	>0.99
Enterocytozoon spp.	0 (0.0)	1 (4.8)	6 (8.6)	>0.99
Schistosoma	0 (0.0)	0 (0.0)	1 (1.4)	>0.99
>1 parasite detected	0 (0.0)	1 (4.8)	8 (11.4)	0.611
Mixed infections				
Virus-bacteria	1 (12.5)	4 (19.1)	9 (12.9)	0.793
Virus-parasite	1 (12.5)	3 (14.3)	12 (17.1)	>0.99
Bacteria-parasite	2 (25.0)	5 (23.8)	21 (30.0)	0.032
•		•	•	

<sup>&</sup>lt;sup>a</sup> CD4+ count within 12 months of enrolment only known for 99 of the 164 HIV-infected cases; <sup>b</sup> The following parasites were screened for but not detected: Vibrio cholerae, Yersinia enterocolitica, E. histolytica, Strongyloides spp., Cyclospora, Hymenolepsis, Ascaris, Taenia, Trichuris, Ancylostoma, Enterobius, Necator, Dientamoeba.

## Table S4: Clinical presentation of HIV-infected cases, stratified by treatment

	Antiretrov	iral treatmer	nt <sup>a</sup> - n (%)	Cotrimoxaz	ole prophyla:	kis <sup>a</sup> - n (%)
	Yes (n=130)	No (n=26)	<i>p</i> -value	Yes (n=63)	No (n=88)	<i>p</i> -value
Duration of symptoms before admission – median (IQR)	5 (3-8)	4.5 (2-10)	0.489	5 (3-9)	4 (3-8)	0.410
Chronic/persistent diarrhoea	10 (7.7)	3 (11.5)	0.456	6 (9.5)	7 (8.0)	0.774
Weight loss	108 (83.1)	19 (73.1)	0.231	57 (90.5)	67 (76.1)	0.023
Fatigue	98 (75.4)	19 (73.1)	0.804	56 (88.9)	61 (69.3)	0.005
Nausea	92 (70.8)	19 (73.1)	0.813	43 (68.3)	65 (73.9)	0.451
Fever (current or self- reported history in the past 10 days)	89 (68.5)	20 (76.9)	0.391	43 (68.3)	61 (69.3)	0.889
Vomiting	89 (68.5)	22 (84.6)	0.153	42 (66.7)	67 (76.1)	0.200
Abdominal pain	83 (63.9)	18 (69.2)	0.600	42 (66.7)	59 (67.1)	0.961
Respiratory symptoms	59 (45.4)	13 (50.0)	0.667	29 (46.0)	41 (46.6)	0.946
Headache	50 (38.5)	12 (46.2)	0.464	30 (47.6)	33 (37.5)	0.214
Chills	39 (30.0)	6 (23.1)	0.477	32 (50.8)	14 (15.9)	<0.001
Arthralgia	32 (24.6)	2 (7.7)	0.069	13 (20.6)	21 (23.9)	0.640
Dermatological symptoms	21 (16.2)	2 (11.5)	0.768	10 (15.9)	14 (15.9)	0.995
Myalgia	14 (10.8)	1 (3.9)	0.469	10 (15.9)	6 (6.8)	0.075
Dysentery b	6 (4.6)	1 (3.9)	>0.99	3 (4.8)	4 (4.6)	>0.99
Neurological symptoms	5 (3.9)	1 (3.9)	>0.99	4 (6.4)	2 (2.3)	0.236
Painful swollen glands	3 (2.3)	0 (0.0)	>0.99	2 (3.2)	1 (1.1)	0.571

<sup>&</sup>lt;sup>a</sup> ART status known for 156 and cotrimoxazole use known for 151 of 164 HIV-infected cases; <sup>b</sup> Dysentery defined as self-reported blood in the stool.

# Table S5: Pathogen detection in specimens of HIV-infected cases, stratified by treatment

	Antiretrovir	al treatment	³ - n (%)	Cotrimoxaz	ole prophylax	is a - n (%)
	No (n=26)	Yes (n=130)	<i>p</i> -value	No (n=88)	Yes (n=63)	<i>p</i> -value
Any pathogen	23 (88.5)	94 (72.3)	0.082	66 (75.0)	49 (77.8)	0.693
Virus	6 (23.1)	32 (24.6)	0.868	20 (22.7)	16 (25.4)	0.704
Adenovirus	3 (11.5)	14 (10.8)	>0.99	9 (10.2)	8 (12.7)	0.795
Adenovirus	0 (0.0)	1 (0.8)	>0.99			
40/41		(		1(1.1)	0 (0.0)	>0.99
Norovirus	3 (11.5)	10 (7.7)	0.456	6 (6.8)	7 (11.1)	0.354
Norovirus GI	0 (0.0)	1 (0.8)	>0.99	1 (1.1)	0 (0.0)	>0.99
Norovirus GII	3 (11.5)	9 (6.9)	0.423	5 (5.7)	7 (11.1)	0.240
Enterovirus	1 (3.9)	8 (6.2)	>0.99	4 (4.6)	4 (6.4)	0.720
CMV	0 (0.0)	3 (2.3)	>0.99	2 (2.3)	1 (1.6)	>0.99
Astrovirus	0 (0.0)	3 (2.3)	>0.99	0 (0.0)	2 (3.2)	0.172
Rotavirus	0 (0.0)	1 (0.8)	>0.99	0 (0.0)	1 (1.6)	0.417
Sapovirus	0 (0.0)	0 (0.0)	-	0 (0.0)	0 (0.0)	-
>1 virus	1 (3.9)	5 (3.9)	>0.99	1 (1.1)	5 (7.9)	0.083
detected						
Bacteria	16 (61.5)	62 (47.7)	0.197	44 (50.0)	32 (50.8)	0.923
Shigella spp.	5 (19.2)	24 (18.5)	>0.99	18 (20.5)	9 (14.3)	0.329
Salmonella spp.	2 (7.7)	10 (7.7)	>0.99	6 (6.8)	5 (7.9)	>0.99
C. difficile	2 (7.7)	10 (7.7)	>0.99	6 (6.8)	6 (9.5)	0.544
Campylobacter	1 (3.9)	10 (7.7)	0.692	4 (4.6)	7 (11.1)	0.202
STEC	0 (0.0)	0 (0.0)	-	0 (0.0)	0 (0.0)	-
ETEC	1 (3.9)	3 (2.3)	0.522	3 (3.4)	1 (1.6)	0.641
EPEC	2 (7.7)	8 (6.2)	0.673	6 (6.8)	5 (7.9)	>0.99
EAEC	2 (7.7)	18 (13.9)	0.531	10 (11.4)	8 (12.7)	0.803
0157	0 (0.0)	3 (2.3)	>0.99	1 (1.1)	2 (3.2)	0.571
Plesiomonas	0 (0.0)	1 (0.8)	>0.99	0 (0.0)	1 (1.6)	0.417
Helicobacter	4 (15.4)	8 (6.2)	0.117	6 (6.8)	6 (9.5)	0.544
pylori						
>1 bacteria	2 (7.7)	24 (18.5)	0.252	11 (12.5)	13 (20.6)	0.178
detected						
Parasite <sup>b</sup>	12 (46.2)	59 (45.4)	>0.99	33 (37.5)	37 (58.7)	0.010
Cystoisospora	4 (15.4)	24 (18.5)	>0.99	10 (11.4)	17 (26.9)	0.014
Cryptosporidium						
spp.	5 (19.2)	21 (16.2)	0.773	12 (13.6)	14 (22.2)	0.168
Blastocystis	4 (15.4)	6 (4.6)	0.063	8 (9.1)	2 (3.2)	0.195
Giardia spp.	1 (3.9)	5 (3.9)	>0.99	4 (4.6)	2 (3.2)	>0.99
Enterocytozoon						
spp.	0 (0.0)	10 (7.7)	0.215	4 (4.6)	6 (9.5)	0.321
Schistosoma	0 (0.0)	4 (3.1)	>0.99	3 (3.4)	1 (1.6)	0.641
>1 parasite						
detected	2 (7.7)	10 (7.7)	>0.99	7 (8.0)	5 (7.9)	>0.99
Mixed						
infections						
Virus-bacteria	3 (11.5)	20 (15.4)	0.768	11 (12.5)	11 (17.5)	0.394
Virus-parasite	2 (7.7)	19 (14.6)	0.531	8 (9.1)	11 (17.5)	0.126

Bacteria-	8 (30.8)	34 (26.2)	0.633	19 (21.6)	22 (34.9)	0.069
parasite						


<sup>a</sup> ART status known for 156 and cotrimoxazole use known for 151 of 164 HIV-infected cases; <sup>b</sup> The following parasites were screened for but not detected: E. histolytica, Strongyloides spp., Cyclospora, Hymenolepsis, Ascaris, Taenia, Trichuris, Ancylostoma, Enterobius, Necator, Dientamoeba.

615

616

617

618



<sup>&</sup>lt;sup>a</sup> Due to limited TAC tests available, cases with unknown HIV status were excluded from the analysis. Controls with unknown HIV status were included to increase sample size for the overall case-control analysis, but were not included in the HIV specific analysis.

Figure 1: Specimens included in the analysis